Voriconazole Tablets, Powder for Oral Suspension, Injection
Recognized Interpretive Criteria
| Minimum Inhibitory Concentrations (mcg/mL) Broth Microdilution at 24 Hours |
Disk Diffusion (zone diameters in mm) Disk Diffusion at 24 Hours |
|||||
|---|---|---|---|---|---|---|
| Pathogen | S | I | R | S | I | R |
| Candida albicans | M27M44S standard is recognized | M27M44S standard is recognized | ||||
| Candida krusei | M27M44S standard is recognized | M27M44S standard is recognized | ||||
| Candida parapsilosis | M27M44S standard is recognized | M27M44S standard is recognized | ||||
| Candida tropicalis | M27M44S standard is recognized | M27M44S standard is recognized | ||||
S = Susceptible; I = Intermediate; R = Resistant
For C. glabrata and voriconazole, current data are insufficient to demonstrate a correlation between in vitro susceptibility testing and clinical outcome.